Physician profile
Ronald E Brown
NPI 1447242060
$1,626.15
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $170 · 2021: $46.11 · 2022: $395 · 2023: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $384.55 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $185.46 | 2019-2023 | Camzyos |
| Boston Scientific Corporation | $166.35 | 2019-2021 | |
| Lilly USA, LLC | $140.92 | 2022-2023 | Jardiance, Mounjaro, Trulicity |
| Pfizer INC. | $127.64 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $106.91 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $63.21 | 2019-2020 | |
| Abbott Laboratories | $59.36 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.03 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $50.98 | 2019-2022 | |
| Novo Nordisk INC | $38.32 | 2022-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $35.58 | 2019-2023 | |
| Exact Sciences Corporation | $31.75 | 2023 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $25.02 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.43 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.26 | 2019 | |
| Hologic Sales and Service, LLC | $17.99 | 2023 | Novasure |
| Glaxosmithkline, LLC. | $16.19 | 2023 | Shingrix, Arexvy |
| Viiv Healthcare Company | $15.91 | 2022 | |
| Lucid Diagnostics INC. | $15.79 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.92 | 2023 | Quviviq |
| Portola Pharmaceuticals, LLC | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.